Dapagliflozin
Back to searchMolecule Structure
Scientific Name
Dapagliflozin
Description of the Drug
Dapagliflozin is a sodium-glucose cotransporter 2 inhibitor used in the management of type 2 diabetes mellitus.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB06292
http://www.drugbank.ca/drugs/DB06292
Brand Name(s)
Forxiga
Company Owner(s)
Zydus Pharmaceuticals Usa Inc, Astrazeneca Ab
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Sodium/glucose cotransporter 2 | SINGLE PROTEIN | INHIBITOR | CHEMBL3884 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL157820 | ||
| DrugBank | DB06292 | ||
| PubChem: Thomson Pharma | 14855234 | 15451267 | |
| PubChem | 9887712 | ||
| Nikkaji | J2.928.717A | ||
| BindingDB | 20880 | 50448923 | |
| DrugCentral | 4304 | ||
| ChemicalBook | CB91011730 | ||
| Guide to Pharmacology | 4594 | ||
| rxnorm | FARXIGA | DAPAGLIFLOZIN PROPANEDIOL | DAPAGLIFLOZIN |
| PubChem: Drugs of the Future | 57304407 | ||
| ChEBI | 85078 | ||
| ZINC | ZINC000003819138 |
